Ligand to receive milestone and royalties as result of FDA approval of ZULRESSO™
Ligand Pharmaceuticals announced it will receive a $3 million milestone payment as a result of the FDA approval of Sage Therapeutics’ ZULRESSOTM (brexanolone) injection for treatment of postpartum depression. ZULRESSO uses Ligand’s Captisol® in its formulation. March 21, 2019